Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
Operating Income
Interpace Biosciences Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Interpace Biosciences Inc
OTC:IDXG
|
Operating Income
$1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
DaVita Inc
NYSE:DVA
|
Operating Income
$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Operating Income
$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
CVS Health Corp
NYSE:CVS
|
Operating Income
$15.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
Cigna Corp
NYSE:CI
|
Operating Income
$9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Operating Income
$1.1B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
See Also
What is Interpace Biosciences Inc's Operating Income?
Operating Income
1.6m
USD
Based on the financial report for Sep 30, 2023, Interpace Biosciences Inc's Operating Income amounts to 1.6m USD.